Skyhawk Teams With Sanofi on Oncology and Immunology Targets in Deal Worth Potentially $2 Billion

Skyhawk Therapeutics, a three-year-old biotech spawned by entrepreneur, inventor and documentary filmmaker Bill Haney, has inked a new deal with Sanofi that has the two companies working together on challenging…

Continue ReadingSkyhawk Teams With Sanofi on Oncology and Immunology Targets in Deal Worth Potentially $2 Billion

CureVac Goes After BioNTech Claiming Patent Infringement by Comirnaty’s mRNA Underpinnings

CureVac has filed a patent infringement lawsuit against BioNTech, claiming its messenger RNA (mRNA) technology was used without credit or compensation to create BioNTech’s and Pfizer’s Comirnaty, the world’s first…

Continue ReadingCureVac Goes After BioNTech Claiming Patent Infringement by Comirnaty’s mRNA Underpinnings

FDA Approval Doesn’t Substantially Increase Access to Novel Treatments for Some Populations, Study

FDA approval alone does not ensure “the optimal administration” of novel treatments like immunotherapy for traditionally underserved populations, according to the authors of a study published in JAMA Network Open.…

Continue ReadingFDA Approval Doesn’t Substantially Increase Access to Novel Treatments for Some Populations, Study